Cancer Risk in Individuals Who Have a Xeroderma Pigmentosum Gene Alteration Compared With Those Who Don't



Status:Archived
Conditions:Cancer, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011

Use our guide to learn which trials are right for you!

Cancer Risk In Xeroderma Pigmentosum Heterozygotes


RATIONALE: Screening individuals who have a xeroderma pigmentosum gene alteration may help
doctors identify persons at risk of developing cancer and identify other cancer genes.

PURPOSE: This clinical trial is comparing cancer risk in individuals who have a xeroderma
pigmentosum gene alteration to those who don't.


OBJECTIVES:

- Compare risk of developing any type of cancer in participants who are heterozygous
carriers of xeroderma pigmentosum (XP) disease gene mutations vs non-carrier blood
relatives or spouses.

- Compare risk of developing skin cancers or cancers of the nervous system in these
participants.

- Compare cancer risk in different groups among heterozygous carriers of XP disease gene
mutations.

- Compare cancer risk in carriers of different XP disease gene mutations with
heterozygous carriers of these gene mutations.

OUTLINE: Participants undergo general cancer screening comprising a medical history and
physical examination, including a skin and neurologic examination. Laboratory samples are
collected for review.

Participants are followed annually by telephone or mail to determine clinical status.

PROJECTED ACCRUAL: Approximately 800 participants (400 heterozygous carriers and 400
non-carrier blood relatives or spouses) will be accrued for this study.


We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
1-800-422-6237
National Cancer Institute (NCI) The National Cancer Institute (NCI) is part of the National Institutes...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials